# Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months

> **NCT00385320** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2640 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** HRV vaccine

## Key facts

- **NCT ID:** NCT00385320
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05-31
- **Primary completion:** 2003-04-30
- **Final completion:** 2003-04-30
- **Target enrollment:** 2640 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385320, "Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00385320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*